EOS 200271

Drug Profile

EOS 200271

Alternative Names: EOS200271; PF 06840003

Latest Information Update: 13 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator iTeos Therapeutics
  • Developer iTeos Therapeutics; Ludwig Institute for Cancer Research
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glioma
  • Preclinical Cancer

Most Recent Events

  • 06 Feb 2018 Pfizer reinitiates a phase I trial for Glioma (Late-stage disease, Recurrent) in USA (PO) (NCT02764151)
  • 12 Jan 2018 Pfizer suspends patient enrolment in a phase I trial in Glioma (Late-stage disease, Recurrent) in USA (PO) (NCT02764151)
  • 04 Jan 2018 iTeos Therapeutics regains exclusive worldwide rights from Pfizer to develop and commercialise EOS 200271 in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top